The unfavorable prognosis associated with the low expression of E-cad may be a clinically reliable tumor biomarker together with other clinicopathological variables in the decision of the treatment to be used in patients affected by this disease, such as a greater margin of surgical intervention or a combination with radiotherapy/chemotherapy [33]. Here, CDH1 is linked to neoplasm.